PPA
INO icon

Parametric Portfolio Associates’s Inovio Pharmaceuticals INO Stock Holding History

Parametric Portfolio Associates’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$442K Sell
10,264
-1,075
-9% -$48.4K ﹤0.01% 3145
2021
Q4 		$679K Buy
11,339
+377
+3% +$30.2K ﹤0.01% 2942
2021
Q3 		$942K Sell
10,962
-1,918
-15% -$192K ﹤0.01% 2826
2021
Q2 		$1.43M Buy
12,880
+1,559
+14% +$150K ﹤0.01% 2608
2021
Q1 		$1.26M Buy
11,321
+1,998
+21% +$263K ﹤0.01% 3047
2020
Q4 		$990K Sell
9,323
-1,457
-14% -$194K ﹤0.01% 3060
2020
Q3 		$1.5M Sell
10,780
-2,153
-17% -$449K ﹤0.01% 2671
2020
Q2 		$4.18M Buy
12,933
+2,817
+28% +$452K ﹤0.01% 1999
2020
Q1 		$903K Sell
10,116
-67
-0.7% -$4.13K ﹤0.01% 2854
2019
Q4 		$403K Buy
10,183
+4,828
+90% +$145K ﹤0.01% 3444
2019
Q3 		$132K Buy
5,355
+2,469
+86% +$75.1K ﹤0.01% 3787
2019
Q2 		$102K Buy
2,886
+1,226
+74% +$48.7K ﹤0.01% 3840
2019
Q1 		$74K Buy
1,660
+415
+33% +$20.9K ﹤0.01% 3849
2018
Q4 		$60K Buy
1,245
+261
+27% +$15.9K ﹤0.01% 3833
2018
Q3 		$66K Sell
984
-1,103
-53% -$61.4K ﹤0.01% 3891
2018
Q2 		$98K Sell
2,087
-15,367
-88% -$848K ﹤0.01% 3811
2018
Q1 		$986K Sell
17,454
-1,296
-7% -$70.1K ﹤0.01% 3027
2017
Q4 		$929K Buy
18,750
+3,008
+19% +$186K ﹤0.01% 3054
2017
Q3 		$1.2M Buy
+15,742
New +$1.17M ﹤0.01% 2921
2016
Q4 		– Sell
-1,747
Closed -$195K – 3791
2016
Q3 		$195K Sell
1,747
-3,659
-68% -$404K ﹤0.01% 3578
2016
Q2 		$599K Buy
+5,406
New +$657K ﹤0.01% 3090
2015
Q4 		– Sell
-1,470
Closed -$102K – 3968
2015
Q3 		$102K Sell
1,470
-129
-8% -$11.2K ﹤0.01% 3186
2015
Q2 		$157K Buy
+1,599
New +$171K ﹤0.01% 3811
2015
Q1 		– Sell
-2,399
Closed -$264K – 3969
2014
Q4 		$264K Sell
2,399
-88
-4% -$10.8K ﹤0.01% 3649
2014
Q3 		$294K Buy
2,487
+157
+7% +$19.6K ﹤0.01% 3469
2014
Q2 		$302K Buy
+2,330
New +$275K ﹤0.01% 3521

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parametric Portfolio Associates's INO Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Inovio Pharmaceuticals (INO) stake by 9.5% in Q1 2022, selling an estimated $48.4K and leaving 10,264 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

Parametric Portfolio Associates first reported a position in INO in Q2 2014 and has held it in 26 quarters since. The position peaked at $4.18M in Q2 2020. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

  • Parametric Portfolio Associates held 10,264 shares of Inovio Pharmaceuticals worth $442K as of Q1 2022.
  • Parametric Portfolio Associates sold 1,075 Inovio Pharmaceuticals shares in Q1 2022, an estimated $48.4K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3145 holding.
  • Parametric Portfolio Associates first reported a position in Inovio Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
  • Parametric Portfolio Associates's Inovio Pharmaceuticals position peaked at $4.18M in Q2 2020.
  • 198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.